International Isotopes Inc. Reports Decline in Q3 Revenue and Increased Net Losses for 2025

International Isotopes Inc. (INIS) reported its financial results for the third quarter and the first nine months of 2025, revealing a decline in revenue and an increase in net losses compared to the same periods in 2024. For the three months ended September 30, 2025, the company generated $3.28 million in product sales, a decrease of approximately 16% from $3.92 million in the prior year. The nine-month revenue also saw a modest increase to $10.17 million, up 2% from $10.00 million in 2024. The net loss for the third quarter was $203,601, a significant drop from a net income of $150,251 in the same quarter of 2024. For the nine months, the net loss widened to $477,080 from $237,245 in the previous year.

The decline in quarterly revenue was primarily attributed to a temporary outage of an isotope supplier affecting the Theranostics Products segment, which saw a 32% drop in sales to $1.48 million. This was partially offset by increased sales in the Calibration & Reference Products segment, which grew by 4% to $961,093, and the Medical Device Products segment, which reported its first sales of $65,757. The Cobalt Products segment also experienced a decrease in sales, down 6% to $766,682. The company noted that it estimated lost sales of approximately $400,000 in the third quarter due to supply chain disruptions.

Operationally, International Isotopes has been focusing on its core business segments, including Theranostics, Cobalt, and Calibration & Reference Products, while also developing its Medical Device segment. The company has made strategic moves, such as acquiring assets from AMICI, Inc. in 2023 and entering into joint ventures to expand its product offerings. The company is also in the process of divesting its Fluorine Products segment, with a definitive agreement to sell related assets for $12.5 million, contingent on regulatory approvals.

As of September 30, 2025, the company reported total assets of $17.85 million, an increase from $17.16 million at the end of 2024. Current liabilities rose to $3.69 million from $3.33 million, while total liabilities increased to $13.75 million from $12.81 million. The company’s cash and cash equivalents decreased to $1.65 million from $1.95 million, reflecting ongoing investments in property and equipment. Despite the challenges, management expects that cash from operations, along with potential equity or debt financing, will be sufficient to fund operations for the next twelve months.

Looking ahead, International Isotopes aims to stabilize sales in its Theranostics Products segment and continue to develop its Medical Device offerings. The company is optimistic about future growth opportunities, particularly in the expanding theranostics market, which is projected to grow significantly in the coming years. However, the company also acknowledges the uncertainties related to market conditions and regulatory approvals that could impact its operations and financial performance.